Carl Icahn
Carl Icahn's Portfolio
| Ticker | # of Shares | Price | Value | |
|---|---|---|---|---|
| CVI | 71,198,718 | $54.05 | $3,848,290,708 | |
| NFLX | 5,541,066 | $233.65 | $1,294,670,071 | |
| FRX | 30,662,005 | $42.21 | $1,294,243,232 | |
| CHK | 59,698,689 | $20.95 | $1,250,687,535 | |
| RIG | 20,154,035 | $49.49 | $997,423,193 | |
| HLF | 16,966,485 | $47.98 | $814,051,951 | |
| FDML | 76,697,804 | $10.51 | $806,093,921 | |
| HLF | 16,355,131 | $47.98 | $784,719,186 | |
| NUAN | 33,899,274 | $18.92 | $641,374,265 | |
| HAIN | 7,239,963 | $67.59 | $489,349,100 | |
| View Additional Portfolio Information » | ||||
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
-
Carl Icahn's Q1 13F Reveals Little New
-
Carl Icahn Releases Q1 13F
-
Carl Icahn Raises FreightCar (RAIL), El Paso (EP) Stakes, Sells Remaining Clorox (CLX)
-
Carl Icahn Files Q3 13F
-
Carl Icahn Liquidates Biogen Idec (BIIB), Chesapeake Energy (CHK); Targets Oshkosh (OSK), Forest Labs (FRX) and Commercial Metals (CMC)
-
Hain Celestial (HAIN) Has the Right Gluten-Free Ingredients for Gains - Cramer
-
Icahn's Icahn Capital Shows New Stake in Amgen (AMGN), Clorox (CLX) and Southern Union (NYSE: SUG); Raises Dynegy (DYN), Lowers Chesapeake (CHK)
-
Icahn Adds More to Hain Celestial Stake
-
Icahn Hangs on to Pharmas, Makes Housing Play, Increases Lions Gate Holding in Recent 13F (MOT, MAS, HAIN, More...)
-
Carl Icahn Shows New Stakes In Energy Names and a Gun Maker (APC, NRG, SWHC)
-
Hain Celestial (HAIN) and Carl Icahn Reach Agreement; Brett Icahn and David Schechter Appointed to Board
-
Icahn Goes Organic (HAIN)
-
After-Hours Movers 5/13: BSMD, EFOI, HAIN, BIDZ Higher; BBI, XRM, COSI, CA, QTM Lower
-
Icahn Reports 11.92% Stake in The Hain Celestial Group (HAIN)
-
Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
